Voyager Therapeutics announces positive interim results from phase 1b trial of VY-AADC01
Voyager Therapeutics announced positive results from the ongoing Phase 1b trial of VY-AADC01 at six and twelve months of follow-up in patients with advanced Parkinson’s. Interim data from Cohorts 1 and 2 of the trial demonstrated escalating doses of VY-AADC01 were well tolerated. December 07, 2016